Jobs
View more job listings or post a job
Genentech Senior/Principal Scientific Researcher (Cell-based Assay Development), BioAnalytical Sciences Department, Genentech
University of California, Davis PHARMACOLOGY TECHNICIAN (SRA 2, NEX)
Vir Biotechnology Director, Regulatory Affairs
Vir Biotechnology Senior Director, Business Development
Vir Biotechnology Senior Scientist, Host Directed Therapy, Click here to apply
PTC Therapeutics Director, Clinical Pharmacology
Alturas Analytics Quality Assurance Director
MCure Biosciences Scientist or Research Associate
Cytokinetics Director/Senior Director, DMPK
Inotiv Senior Toxicologist / Study Director
Post a job

Symposium

Covalent Inhibitor Drug Discovery & Development: Biology, Chemistry, PK, Safety and Case Studies (Jointly with Bay Area PKPD Network)


Speakers: Tom Baillie (Univ Washington), Jack Taunton (UCSF), Joachim Rudolph (Genentech), Dane Karr (Nurix), Zhengping Wang (Revolution Medicine), Shirin Kapur (ex-Onyx), Leah Schutt- (Genentech), Betty Chang (ex-Pharmacyclics)
Organizers: Xu (Richard) Zang, PhD (Genentech)
Date: 2019-02-07
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location: Crowne Plaza, Foster City, CA
Major Sponsor: (1)Correlia Biosystems;(Major Sponsorship - Afternoon still open)
Vendor show vendors registered to date: (20)AIT Bioscience; Alturas Analytics; Averica Discovery Services; BioDuro; BioreclamationIVT; cgenetool; CMIC Inc.; Cytovier LLC; Intertek; MagArray; MedChemExpress; Medpace; MicroConstants; MRIGlobal; Nucleo Life Sciences; Q2 Solutions; Sekisui XenoTech, LLC; Selvita Inc.; Seventh Wave; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2019-02-04  (it will close sooner if the seating cap is reached)

About the Topic

In recent years, there has been a renewed interest in drug development of covalent inhibitors.  Several of these inhibitors have been approved by the FDA and EMA and more covalent inhibitors are in early and late stage development.  Covalent inhibitors can have superior affinity towards target proteins compared to their non-covalent counterparts, potentially resulting in improved therapeutic benefit.  This symposium will cover a wide range topics pertaining to covalent inhibitors discovery and development

Key Topics:

  • Targeted Covalent Inhibitors for Drug Design – Tom Baillie (UW)
  • Kinetic selectivity with lysine-targeted kinase inhibitors – Jack Taunton (UCSF)
  • Covalent modification in drug discovery - a chemist's perspective – Joachim Rudolph (Genentech)
  • Preclinical challenges for reversible covalent inhibitors – Dane Karr (Principia)
  • Development of covalent proteosome inhibitors: DMPK and clinical pharmacology perspectives – Zhengping Wang (Revolution Medicine)
  • Benchmark for Selective Sustained Proteasome Inhibition – Shirin Kapur (Cortexyme)
  • Safety Considerations for Covalent Inhibitors - Leah Schutt- (Genentech)
  • From bench to bedside: The story of a first-in-class covalent BTK inhibitor ibrutinib– Betty Chang


Agenda:

8:45-8:55           Welcome and overview - Richard Zang / Shichang Miao

8:55-9:40           Targeted Covalent Inhibitors for Drug Design - Tom Baillie

9:40-10:25         Kinetic selectivity with lysine-targeted kinase inhibitors - Jack Taunton

10:25-10:35       Major Sponsor's Presentation

10:35-10:50       Break

10:50-11:35       Covalent modification in drug discovery - a chemist's perspective - Joachim Rudolph

11:35-12:20       Safety Considerations for Covalent Inhibitors - Leah Schutt

12:20-13:20       Lunch

13:20-14:05       Preclinical challenges for reversible covalent inhibitors - Dane Karr

14:05-14:50       From bench to beside:  The story of a first-in-class covalent BTK inhibitor ibrutinib - Betty Chang

14:50-15:00       Major Sponsor's Presentation

15:00-15:15       Break

15:15-16:00       Benchmark for Selective Sustained Proteasome Inhibition - Shirin Kapur

16:00-16:45       Development of covalent proteasome inhibitors: DMPK and clinical pharmacology perspectives - Zhengping Wang

16:45-17:15       Panel Discussion


2022-07-27, [Free Online Symposium] Success Stories and Lessons Learned from Recent FDA Approvals: VOXZOGO (vosoritide) by BioMarin Pharmaceutical Inc.
2022-08-17, [Free Online Symposium] Advances in Oncology
2022-09-15, [Free Online workshop] Immunogenicity of Biologic Drugs – Clinical Relevance case studies, Predictive Tools & Challenges with New modalities
2022-11-02, [Free Online workshop] Bispecific Antibodies: Discovery, Engineering, Development and Regulatory Considerations
2022-11-14, [Free Online Symposium] Advances in Cell therapy
©Pharmaceutical & BioScience Society, International; Last Modified: 6/27/2022; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Synthesis, purification & NMR characterization of phase 1 and 2 drug metabolites at mg-g scale with COAs. Also experts in natural products.
Laviana Pharma Corp Laviana’s new GMP facility will be validated very soon! We’re taking bookings for API, Intermediate & Custom Synthesis and R&D services for Q2-2023
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Veloxity Labs, LLC The unique employee-owned LC-MS/MS bioanalytical CRO with >100 years of experience and the responsiveness of a start-up! GLP and non-GLP.
Submit a Text Ad